Shares of Sophiris Bio Inc (NASDAQ:SPHS) saw strong trading volume on Monday . 1,004,201 shares traded hands during trading, an increase of 258% from the previous session’s volume of 280,653 shares.The stock last traded at $2.05 and had previously closed at $1.89.

A number of brokerages have weighed in on SPHS. HC Wainwright reiterated a “buy” rating and set a $6.00 price target on shares of Sophiris Bio in a report on Friday, September 15th. Maxim Group set a $6.00 price target on Sophiris Bio and gave the stock a “buy” rating in a report on Monday, October 2nd. One analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. Sophiris Bio has a consensus rating of “Buy” and an average target price of $6.25.

The company has a current ratio of 13.37, a quick ratio of 13.37 and a debt-to-equity ratio of 0.60.

An institutional investor recently bought a new position in Sophiris Bio stock. Mesirow Financial Investment Management Inc. purchased a new stake in Sophiris Bio Inc (NASDAQ:SPHS) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 54,510 shares of the biopharmaceutical company’s stock, valued at approximately $120,000. Mesirow Financial Investment Management Inc. owned approximately 0.18% of Sophiris Bio as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 5.56% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This report was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another site, it was copied illegally and reposted in violation of United States & international trademark & copyright laws. The correct version of this report can be viewed at

Sophiris Bio Company Profile

Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).

Receive News & Stock Ratings for Sophiris Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio and related stocks with our FREE daily email newsletter.